Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

James Sapp

Physician Assistant Fredericksburg, VA Physician Assistant

NPI 1013647882 CMS profile 11310078

125 Olde Greenwich Dr Ste 300, Fredericksburg, VA 22408

Open in the dashboard

General payments

$3,475

202 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Sapp of Fredericksburg, VA is reported in the CMS Open Payments database as having received $3,475 across 202 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $70 3
2024 General $1,313 76
2023 General $1,702 101
2022 General $390 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Sapp
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to James Sapp were reported at $70. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year James Sapp Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $390 $155 $48–$522 $149
2023 $1,702 $167 $52–$557 $160
2024 $1,313 $178 $55–$600 $164
2025 $70 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Otsuka America Pharmaceutical, Inc. $537 38 payments
  2. Lilly USA, LLC $450 25 payments
  3. AbbVie, Inc. $421 30 payments
  4. Novo Nordisk Inc $364 18 payments
  5. AstraZeneca Pharmaceuticals LP $243 13 payments
  6. Lundbeck LLC $191 10 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $184 14 payments
  8. GlaxoSmithKline, LLC. $109 7 payments
  9. Pfizer Inc. $107 6 payments
  10. Amgen Inc. $79 4 payments
  11. Other $790 37 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $3,475 202 payments
Products named General payments · program years 2022–2025
  1. REXULTI Psychiatry $523 37 payments
  2. MOUNJARO $266 15 payments
  3. FARXIGA $231 12 payments
  4. QULIPTA $230 12 payments
  5. UBRELVY $229 19 payments
  6. Ozempic $212 10 payments
  7. RYBELSUS $212 10 payments
  8. REXULTI Psychiatry $191 10 payments
  9. EMGALITY $184 10 payments
  10. TRINTELLIX $184 14 payments
  11. Other $1,933 106 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 108 drugs

Part D claims

5,726

Median for Physician Assistant: 241

Drug cost

$356,494

Median for Physician Assistant: $4,110

Branded share of claims

16.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 58 $63,750
Farxiga Dapagliflozin Propanediol Brand 59 $61,323
Trulicity Dulaglutide Brand 26 $40,679
Jardiance Empagliflozin Brand 27 $31,418
Ozempic Semaglutide Brand 21 $31,062
Januvia Sitagliptin Phosphate Brand 24 $25,899
Xarelto Rivaroxaban Brand 11 $13,271
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 11 $9,164
Rosuvastatin Calcium Generic 336 $4,890
Levothyroxine Sodium Generic 302 $3,449

The 10 drugs with the highest cost, of 108 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$49,021

Of which drugs: $777

Medicare patients

423

Average age 75

Services billed

1,129

256 women, 167 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Diabetes 30%
Ischemic heart disease 28%
Chronic kidney disease 23%
Depression 21%
Atrial fibrillation 20%
COPD 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 27 96 $61
Injection, ketorolac tromethamine, per 15 mg J1885 Office 11 30 $14
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 26 85 $6

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $215
  • Lundbeck LLC $95
$310 — —
QULIPTA
  • AbbVie, Inc. $182
$182 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $66
$66 59 —
Qelbree
  • Supernus Pharmaceuticals, Inc. $65
$65 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $61
$61 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

202 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record